Novartis today announced plans to establish a new 46,000-square-foot radioligand therapy (RLT) manufacturing facility in Denton, Texas, as part of its broader strategy to expand advanced cancer treatment capabilities across the United States.
The purpose-built site, expected to be operational by 2028, will serve patients across the Southern US and further strengthen the company’s radioligand therapy manufacturing network — the largest of its kind in the country.
The Denton facility will become Novartis’ fifth RLT manufacturing site in the US and its first in Texas. The expansion comes amid growing demand for radioligand therapies, which are increasingly being studied and used in earlier treatment lines and across additional tumor types.
Radioligand therapy combines a targeting molecule with a radioactive isotope, enabling precision delivery of radiation directly to cancer cells while minimizing damage to surrounding healthy tissue. Because each dose is custom-made and time-sensitive, proximity to treatment centers is essential for reliable delivery.
The Texas site will complement existing US facilities in New Jersey, Indiana and California, along with a recently announced site in Florida, creating coast-to-coast RLT manufacturing capacity.
The new Denton facility is part of Novartis’ broader 23 billion USD investment commitment in the United States. Construction is expected to begin later this year.
The project is anticipated to generate new roles in bioengineering, advanced manufacturing, quality assurance and operations, contributing to economic growth in Denton and the surrounding Dallas-Fort Worth region.
“Radioligand therapy has the potential to transform cancer care,” said Vas Narasimhan, CEO of Novartis. “Expanding our manufacturing footprint in the US strengthens our ability to deliver these next-generation treatments with the speed and precision patients require.”
Texas Governor Greg Abbott welcomed the investment, highlighting the state’s growing biotech and life sciences ecosystem and the role of advanced manufacturing in strengthening domestic supply chains for innovative medicines.
Over the past ten months, Novartis has broken ground on four new manufacturing and R&D facilities, initiated three site expansions and announced two additional locations in the US. The Denton project marks continued progress in scaling infrastructure to meet the rising global demand for advanced cancer therapies.
The company’s RLT manufacturing network has maintained a record of delivering more than 99% of doses on the planned treatment day — a critical benchmark given the highly specialized and time-sensitive nature of radioligand therapies.
With the addition of the Denton facility, Novartis aims to further enhance supply reliability and expand patient access to next-generation cancer treatments across the United States.
